Company Description
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide.
The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; microscopes; protein consumables; industrial filtration products; and genomic medicines, such as custom nucleic acid products, plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX and SCIEX brands.
The Diagnostics segment offers chemistry, immunoassay, microbiology, and automation systems; and molecular, acute care, and pathology diagnostics products.
This segment also provides clinical instruments, reagents, consumables, software, and services for hospitals, physicians’ offices, reference laboratories, and other critical care settings.
The company has a research collaboration with Stanford University's Department of Bioengineering for cancer drug development.
The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984.
Danaher Corporation was founded in 1969 and is based in Washington, the District of Columbia.
| Country | United States |
| Founded | 1969 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| Employees | 63,000 |
| CEO | Rainer Blair |
Contact Details
Address: 2200 Pennsylvania Avenue, North West, Suite 800 West Washington, District of Columbia 20037-1701 United States | |
| Phone | 202 828 0850 |
| Website | danaher.com |
Stock Details
| Ticker Symbol | DHR |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000313616 |
| CUSIP Number | 235851102 |
| ISIN Number | US2358511028 |
| Employer ID | 59-1995548 |
| SIC Code | 3823 |
Key Executives
| Name | Position |
|---|---|
| Rainer M. Blair | President, Chief Executive Officer and Director |
| Steven M. Rales | Co-Founder and Chairman |
| Mitchell P. Rales | Co-Founder and Director |
| Matthew R. McGrew | Chief Financial Officer and Executive Vice President |
| Dr. Jose-Carlos Gutierrez-Ramos Ph.D. | Senior Vice President and Chief Science Officer |
| Georgeann F. Couchara | Senior Vice President of Human Resources |
| Christopher M. Bouda | Vice President and Chief Accounting Officer |
| John Bedford | Vice President of Investor Relations |
| Brian W. Ellis J.D. | Senior Vice President, General Counsel and Chief Compliance Officer |
| Daniel A. Raskas J.D. | Senior Vice President of Corporate Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 11, 2024 | 8-K | Current Report |
| Nov 26, 2024 | 144 | Filing |
| Nov 25, 2024 | 144 | Filing |
| Nov 5, 2024 | 144 | Filing |
| Oct 23, 2024 | 144 | Filing |
| Oct 22, 2024 | 8-K | Current Report |
| Oct 22, 2024 | 10-Q | Quarterly Report |
| Aug 26, 2024 | 144 | Filing |
| Aug 13, 2024 | 144 | Filing |
| Aug 1, 2024 | 144 | Filing |